Advicenne Stock (ALDVI.PA): Analysis & Outlook

Advicenne stock (ALDVI, ISIN FR0013296746) is the share of a French pharmaceutical company specializing in rare kidney diseases, listed on Euronext Growth Paris. Its lead product, Sibnayal®, treats distal renal tubular acidosis. In 2026, the story is one of sharp contrasts: the first half-year profit in its history, but also a safeguard procedure and the withdrawal of its application for authorization in the United States.

This page explains the Advicenne share price, what moves it, the safeguard procedure and its consequences for shareholders, the latest results, the markets for Sibnayal and how to buy the shares — together with the high risks that come with an indebted micro-cap.

Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Last updated: 21 October 2026

Advicenne Share Price: Live Quote

Shares of currently trade at €, a move of % over the session. Over 52 weeks, the stock has traded between € and €.

The reference quotation for Advicenne ALDVI is Euronext Growth Paris. Volumes traded there are thin: on a micro-cap, a few orders are enough to move the price by several percent, up as well as down. A limit order is essential.

Advicenne in Brief: A Rare Kidney Disease Specialist

Advicenne develops and commercializes treatments for rare kidney diseases, in children as well as adults. Its expertise lies in reformulation: making an existing treatment simpler to take, more consistent in its effect and better tolerated. The company is headquartered in Paris, with teams in France and the United States.

The core of the portfolio is Sibnayal® (ADV7103), a combination of potassium citrate and potassium bicarbonate in extended-release granules. It was approved in 2021 by the European Medicines Agency (EMA) and by the UK authority the MHRA, for patients aged one year and over with distal renal tubular acidosis (dRTA).

dRTA is a disease in which the kidneys do not remove enough acid through the urine. The acid builds up in the blood, with consequences for growth, hearing, the formation of kidney stones and potassium levels. Conventional alkalinizing treatments often require several doses across the day; the extended-release formulation of Sibnayal is designed to reduce that burden.

The group also markets Likozam® in France, and is exploring a second indication for ADV7103: cystinuria, another rare hereditary kidney disease responsible for recurring stones. Beyond Sibnayal, this second indication is the main driver of the Advicenne pipeline.

Why the Advicenne Share Price Moves So Much

On a small biotech, price moves do not follow the logic of a large-cap stock. Five families of events explain most of the volatility in the ALDVI shares:

• Funding: limited cash, capital raises and bond issues. Every new financing can dilute existing shareholders.
• The safeguard procedure: its milestones — the end of the observation period, a plan proposed to creditors, the court decision — are major catalysts.
• Regulation: approvals, reimbursements and price negotiations, country by country.
• Sales and royalties: the growth in the number of patients treated and in the royalties paid by distributors.
• Liquidity: with few trades each day, a single impatient seller is enough to send the price down.

Two sessions illustrate this sensitivity. On 6 May 2026, the day after the safeguard procedure was announced, the stock lost 27.4% in a single session, according to BFM Bourse. Advicenne news 2026 kept coming: in late August, the withdrawal of the US filing weighed on the shares again.

The Safeguard Procedure Explained for Shareholders

On 5 May 2026, the Tribunal des activités économiques de Paris opened a safeguard procedure (sauvegarde) for the benefit of Advicenne. The company, which had spent several months in out-of-court negotiations with its creditors, chose this framework to restructure its entire debt on better terms.

When the procedure opened, debt stood at €29.2 million: €16.5 million owed to the European Investment Bank (EIB), €2.4 million of loans guaranteed by the State and €10.3 million due to the French State. The last of these stems from the 2021 early access reform, which required the company to hand back up to 80% of the revenue it generated in France for as long as the price remained unset.

A safeguard is neither a bankruptcy nor a liquidation. It is a preventive procedure, open to a company that is not insolvent: it freezes earlier debts during an observation period and buys time to build a plan. For Advicenne, the observation period runs until 5 November 2026 and can be extended until 6 May 2027.

What It Could Mean for Your Shares

Several outcomes are possible, and none is guaranteed. A safeguard plan can spread the debts over several years, which preserves the company but weighs on its future cash. A conversion of debt into equity would cut the indebtedness, at the cost of heavy dilution for current shareholders. If it fails, the procedure can turn into receivership (redressement judiciaire), a scenario in which shareholders are generally the last to be served.

Analyst commentary has remained cautious. Allinvest Securities, quoted by BFM Bourse, judged that the move, even though presented as voluntary and preventive, confirmed that the debt had become difficult to keep ‘manageable’ within a purely out-of-court framework.

First-Half 2026 Results: A First Profit to Read With Caution

On 17 September 2026, Advicenne reported a positive net result of €4.62 million for the first half, against a loss of €4.96 million a year earlier — a first in its history. The figure nevertheless deserves a detailed reading, because it rests largely on non-recurring items.

Source: half-year accounts as of 30 June 2026, as reported by ABC Bourse. Recurring operating income remains negative. The profit comes from the reversal of a €1.3 million provision linked to Likozam early access and from the offsetting of early access rebates after the price agreements concluded in France. In other words, the ongoing business does not yet cover its costs.

The positive points are real: Sibnayal sales in France up 41% in volume, royalties up 45%, and revenue from the end markets served by its distributors up 27%. Net debt fell by about €6 million, to €25.5 million, thanks to the offsetting of the early access debts. Financial income, for its part, remains negative because of the cost of the restructured debt.

Sibnayal: Markets, Reimbursement and the US Filing

The value of Advicenne depends almost entirely on the rollout of Sibnayal. The product is sold in Europe and the Middle East, directly in France and through distributors elsewhere, who pay royalties.

• France: reimbursed by the Sécurité sociale, the French public health system, since February 2026, after a price agreement with the Comité économique des produits de santé (CEPS). The price came down when early access ended, but volumes are growing.
• Spain: reimbursement secured in July 2026, after long years of negotiations.
• United Kingdom: authorization validated by the MHRA.
• Saudi Arabia: approved and reimbursed since 2025.

The United States was the great hope of the story: the most lucrative market for orphan drugs, with orphan drug designation obtained in 2022. In August 2026, however, Advicenne withdrew its ADV7103 marketing application, because of additional work required on the manufacturing and quality control part (CMC) that could not be completed within the timeline of the ongoing review.

The company says it is assessing its options to unlock the value of ADV7103 in the United States and to continue its discussions with potential partners. A US partnership remains the main possible positive catalyst — but nothing guarantees that it will materialize, nor on what terms.

Stock Market History: From IPO to the Fall

Advicenne went public on 6 December 2017 on Euronext Paris, at a price of €14.03 per share. On 30 March 2022, the company moved its shares from Euronext Paris and Euronext Brussels to Euronext Growth Paris, a market with lighter obligations, designed for small caps.

In between, the French early access reform of 2021 weighed heavily on cash, and the cost of the US filing accelerated the cash burn. By the time of the safeguard procedure, the stock had wiped out almost all of its value relative to its IPO price. That trajectory is a reminder that a marketing approval is not enough: a price, a reimbursement and durable funding still have to be secured.

Advicenne Stock: Key Figures

The gauge positions the current price within the range of the last 52 weeks:

The last five trading sessions of :

According to the company website, Advicenne has 14,219,619 shares outstanding. The market capitalization — the price multiplied by the number of shares — places the stock among the micro-caps of the Paris market. That share count can rise in the event of a bond conversion or a capital increase.

Market Data and History, Updated Automatically

Source: Yahoo Finance, data collected by the server (collection date shown under each block). PER not shown: the value provided by the source is inconsistent with the latest published accounts. Indicative data only, not investment advice.

Ouvrir un compte Vantage →

Cash and Financing: The Runway Extends, Dilution Lurks

At the end of 2025, net cash was down to €1.34 million, against €3.24 million a year earlier, according to the annual results. In June 2026, Advicenne put in place a bond financing of up to €3.8 million in nominal amount, with an initial net drawdown of €1.4 million.

In October 2026, the company announced it had received the balance of this financing, arranged with a fund managed by L1 Capital, and that its financial visibility now extends to 2028. That is good news for business continuity.

For shareholders, the key question is the nature of these financings. At small biotechs, bonds subscribed by specialist funds are often convertible into shares, which can bring progressive dilution and selling pressure on the price. Before buying, read the exact terms in the company press releases.

Analyst Consensus on Advicenne Stock

The stock is followed by very few analysts, which makes the consensus fragile: a single change of opinion can move the average target price. For a company in safeguard proceedings, price targets depend heavily on assumptions about the outcome of the negotiations and on a possible US partnership.

Advicenne Dividend Policy

Advicenne pays no dividend, and this is unlikely to change. A company in safeguard proceedings devotes its cash to repaying its creditors and funding its operations; a distribution to shareholders is not on the table in this framework.

The stock can therefore offer only a potential capital gain if the price recovers. Investors looking for regular income will do better with established yield stocks.

Competition and Advicenne’s Place Among French Biotechs

In dRTA, the main competition for Sibnayal comes from conventional alkalinizing treatments: citrate or bicarbonate preparations, inexpensive but cumbersome to take several times a day. The Advicenne argument is simpler dosing and a more consistent effect; its challenge is convincing payers to reimburse a higher price.

More broadly, Advicenne belongs to the biotech small caps France lists in Paris, a highly heterogeneous universe. Our guide to investing in biotech stocks explains how to assess these companies: cash, funding runway, pipeline and regulatory risk.

For comparison, Transgene stock illustrates another French biotech model, centered on clinical research in oncology, while Guerbet stock represents a laboratory that is already profitable, specialized in medical imaging.

Is Advicenne a Good Investment in 2026?

Advicenne stock is a highly speculative play. The positive scenario does exist: growing European sales, reimbursement secured in France and Spain, lower debt, an extended cash runway and a possible US partnership. In that case, a deeply discounted stock can react sharply.

The negative scenario is just as concrete: an unfavorable outcome of the safeguard, massive dilution through debt or bond conversions, no partner in the United States, and a core business still in the red. In that case, the loss can be total.

If you nonetheless intend to invest, a few rules of caution apply:

• Commit only a very small share of your portfolio, money you accept you may lose.
• Follow the press releases: the end of the observation period in November 2026, the safeguard plan, the financings.
• Use limit orders exclusively, given the low liquidity.
• Avoid piling in after a sharp rally driven by a rumor.

How to Buy Advicenne Stock

1. Identify the stock: Advicenne, mnemonic ALDVI, ISIN FR0013296746, market Euronext Growth Paris. Check the listing venue so you do not end up trading a less liquid foreign line.
2. Choose the account wrapper: as a French company, Advicenne is eligible for the PEA and the PEA-PME, the French tax-advantaged equity plans that exempt capital gains from income tax after five years. With a stock this risky, a plain securities account (compte-titres) instead lets you offset a potential loss against other gains.
3. Choose your broker: check that it gives access to Euronext Growth and compare the fees for small amounts.
4. Place a limit order: our guide to stock market orders explains why a market order is dangerous on a thinly traded stock.
5. Follow the calendar: annual results in the spring, half-year results in September, and the milestones of the safeguard procedure.

Leveraged products such as CFDs are particularly ill-suited to such a volatile and illiquid micro-cap: the bid-ask spread and the abrupt swings can lead to rapid losses.

Advicenne Stock: Frequently Asked Questions

Diversifiez votre patrimoineInvestissez dans l’artDes tableaux originaux, pièces uniques signées par l’artiste. Un actif tangible, loin des écrans et des cotations.Voir les tableaux →

Key Takeaways

• Listing: Euronext Growth Paris, ALDVI, ISIN FR0013296746 — eligible for the PEA and the PEA-PME.
• Business: rare kidney diseases, with Sibnayal for distal renal tubular acidosis.
• Situation: safeguard procedure opened on 5 May 2026, observation until 5 November 2026 (extendable).
• Results: first half-year profit in 2026, driven by non-recurring items; the core business is still loss-making.
• Catalysts: the safeguard plan, a US partnership, growth in European sales.
• Risk: very high — dilution and total loss are possible; no dividend.